‡ When “Portfolio Reflex” is selected on the test requisition form (TRF), Foundation Medicine will proceed with the initial test and if the specimen does not meet the criteria for successful testing, we will automatically reflex to the other test and procure a new specimen. ...
The powerful neural network finds a needle in a haystack. Advanced 3D imaging and analysis provide a unique view of the tissue. And genetic testing helps confirm the early diagnosis. All this provides patients and their physicians with reliable diagnostic testing based on the most advanced science...
Routine clinical use of CDx testing has already detected thousands of precancers and cancers that would otherwise have been missed in time for effective endoscopic treatment. CDx Diagnostics is looking to apply the WATS3D platform to prevent cancers of the bile duct, stomach, and colon. Learn mor...
Most clinical development programs require testing to occur in sites across the globe, and we have harmonized CDx SOPs. Our on-site pathologists are trained across indications and IHC cut-off evaluations by the IVD company for IHC cut-off evaluations, and we dedicate CDx study coordinators and ...
BioDuro CDX tumor models are used primarily in drug efficacy studies, providing reproducible and cost-effective solutions for efficacy testing and drug screening in cancer research. We have more than 270 CDX models available, covering 20 human cancer types. Each well-characterized CDX model includes...
Meeting minimum safety and effectiveness performance standards is essential for CDx testing, and a thorough understanding of regulatory considerations is necessary to plan and design the optimal product. In this review, we focus on the diagnostic field of precision medicine and discuss the safety and ...
When FoundationOne Liquid CDx results were negative and ctDNA tumor fraction was Low, reflexing to tissue testing with FoundationOne CDx found previously unidentified alterations in 52% of patient samples.6 Image High ctDNA Tumor Fraction When ctDNA tumor fraction was High, reflexing to tissue ...
Welcome to the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe With drug-diagnostic co-development partnerships fueling advances in diagnostic testing for Alzheimer’s, Multiple Sclerosis, cardiovascular disease, rare genetic disorders, and cancer, 2025 is poised as a critical year ...
Better Answers, Faster: The use of our in-house reagent and immunoassay portfolios accelerates the timeline from discovery to assay development, enabling the deployment of an analytically validated assay for clinical sample testing at speed. Capacity to Scale: Our end-to-end solution utilizing ou...
“As the healthcare system works to realize the impact of precision medicine, patients must have access to the proper testing that helps unlock targeted treatment options based on their unique genomic profiles. This access is the driving motivation behind the extensive work we...